001 | 889388 | ||
005 | 20240704133552.0 | ||
024 | 7 | _ | |2 HSB |a eva494216 |
024 | 7 | _ | |2 ISSN |a 0009-9236 |
024 | 7 | _ | |2 ISSN |a 1085-8733 |
024 | 7 | _ | |2 ISSN |a 1532-6535 |
024 | 7 | _ | |2 SCOPUS |a SCOPUS:2-s2.0-85118938988 |
024 | 7 | _ | |2 WOS |a WOS:000727322700001 |
024 | 7 | _ | |2 datacite_doi |a 10.18154/RWTH-CONV-250487 |
024 | 7 | _ | |2 doi |a 10.1002/cpt.2461 |
024 | 7 | _ | |2 pmid |a pmid:34689339 |
037 | _ | _ | |a RWTH-CONV-250487 |
041 | _ | _ | |a English |
100 | 1 | _ | |a Flynn, Robert |b 0 |
245 | _ | _ | |a Marketing authorization applications made to the european medicines agency in 2018–2019: what was the contribution of real-world evidence? |h online, print |
260 | _ | _ | |c 2021 |
336 | 7 | _ | |0 0 |2 EndNote |a Journal Article |
336 | 7 | _ | |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |a Journal Article |b journal |m journal |
336 | 7 | _ | |2 BibTeX |a ARTICLE |
336 | 7 | _ | |2 DRIVER |a article |
336 | 7 | _ | |2 DataCite |a Output Types/Journal article |
336 | 7 | _ | |2 ORCID |a JOURNAL_ARTICLE |
500 | _ | _ | |a First published: 24 October 2021 |
591 | _ | _ | |a Germany |
591 | _ | _ | |a Netherlands |
591 | _ | _ | |a UK |
700 | 1 | _ | |a Plueschke, Kelly |b 1 |
700 | 1 | _ | |a Quinten, Chantal |b 2 |
700 | 1 | _ | |a Strassmann, Valerie |b 3 |
700 | 1 | _ | |a Duijnhoven, Ruben G. |b 4 |
700 | 1 | _ | |a Gordillo-Marañon, Maria |b 5 |
700 | 1 | _ | |0 P:(DE-588)1205575669 |a Rückbeil, Marcia Viviane |b 6 |u rwth |
700 | 1 | _ | |a Cohet, Catherine |b 7 |
700 | 1 | _ | |a Kurz, Xavier |b 8 |e Corresponding author |
773 | _ | _ | |0 PERI:(DE-600)2040184-X |a 10.1002/cpt.2461 |n 1 |p 90-97 |t Clinical pharmacology & therapeutics |v 111 |x 1532-6535 |
856 | 4 | _ | |u https://publications.rwth-aachen.de/record/889388/files/889388.pdf |y OpenAccess |
909 | C | O | |o oai:publications.rwth-aachen.de:889388 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
910 | 1 | _ | |0 I:(DE-588b)36225-6 |6 P:(DE-588)1205575669 |a RWTH Aachen |b 6 |k RWTH |
914 | 1 | _ | |y 2021 |
915 | 1 | _ | |0 StatID:(DE-HGF)0031 |2 StatID |a Peer reviewed article |x 0 |
915 | _ | _ | |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |
915 | _ | _ | |0 StatID:(DE-HGF)0100 |2 StatID |a JCR |b CLIN PHARMACOL THER : 2021 |d 2022-11-11 |
915 | _ | _ | |0 StatID:(DE-HGF)0113 |2 StatID |a WoS |b Science Citation Index Expanded |d 2022-11-11 |
915 | _ | _ | |0 StatID:(DE-HGF)0150 |2 StatID |a DBCoverage |b Web of Science Core Collection |d 2022-11-11 |
915 | _ | _ | |0 StatID:(DE-HGF)0160 |2 StatID |a DBCoverage |b Essential Science Indicators |d 2022-11-11 |
915 | _ | _ | |0 StatID:(DE-HGF)0199 |2 StatID |a DBCoverage |b Clarivate Analytics Master Journal List |d 2022-11-11 |
915 | _ | _ | |0 StatID:(DE-HGF)0200 |2 StatID |a DBCoverage |b SCOPUS |d 2022-11-11 |
915 | _ | _ | |0 StatID:(DE-HGF)0300 |2 StatID |a DBCoverage |b Medline |d 2022-11-11 |
915 | _ | _ | |0 StatID:(DE-HGF)0510 |2 StatID |a OpenAccess |
915 | _ | _ | |0 StatID:(DE-HGF)1030 |2 StatID |a DBCoverage |b Current Contents - Life Sciences |d 2022-11-11 |
915 | _ | _ | |0 StatID:(DE-HGF)1050 |2 StatID |a DBCoverage |b BIOSIS Previews |d 2022-11-11 |
915 | _ | _ | |0 StatID:(DE-HGF)1110 |2 StatID |a DBCoverage |b Current Contents - Clinical Medicine |d 2022-11-11 |
915 | _ | _ | |0 StatID:(DE-HGF)1190 |2 StatID |a DBCoverage |b Biological Abstracts |d 2022-11-11 |
915 | _ | _ | |0 StatID:(DE-HGF)3001 |2 StatID |a DEAL Wiley |d 2022-11-11 |w ger |
915 | _ | _ | |0 StatID:(DE-HGF)9905 |2 StatID |a IF >= 5 |b CLIN PHARMACOL THER : 2021 |d 2022-11-11 |
920 | 1 | _ | |0 I:(DE-82)526501-1_20140620 |k 526501-1 |l Institut und Lehr- und Forschungsgebiet Medizinische Statistik |x 0 |
970 | _ | _ | |a eva494216 |
980 | 1 | _ | |a FullTexts |
980 | _ | _ | |a I:(DE-82)526501-1_20140620 |
980 | _ | _ | |a UNRESTRICTED |
980 | _ | _ | |a VDB |
980 | _ | _ | |a journal |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|